Barinthus Biotherapeutics Drug Pipeline

Company details

Drug portfolio

5 compounds

diphtheria (d), tetanus (t), pertussis (acellular, component) (pa), hepatitis b (rdna) (hbv), poliomyelitis (inactivated) (ipv) and haemophilus influenzae type-b (hib) conjugate vaccine (adsorbed)
Antiinfectives for systemic use (J07)

Antiinfectives for systemic use (J07) compound in Barinthus Biotherapeutics's portfolio.
ethinyl estradiol

US regulatory status: approved. Molecular target: Estrogen receptor.

Target

Estrogen receptor

Mechanism

Estrogen receptor alpha agonist
influenza vaccine (h1n1)v (split virion, inactivated, adjuvanted)
Antiinfectives for systemic use (J07)

Antiinfectives for systemic use (J07) compound in Barinthus Biotherapeutics's portfolio. Mechanism: Biological vaccine - induces immune response.

Mechanism

Biological vaccine - induces immune response
influenza vaccine (live attenuated, nasal)
Antiinfectives for systemic use (J07)

Antiinfectives for systemic use (J07) compound in Barinthus Biotherapeutics's portfolio.
vaccine

Development asset linked to Barinthus Biotherapeutics in public FDA and regional records.